聚腺苷二磷酸核糖聚合酶抑制剂的抗肿瘤研究近况  

Research Status of Poly ( ADP-ribose) Polymerase Inhibitors in Anti-tumor Therapy

作　　者：张雪媛[1] 孙建国[1] 彭英[1] 王广基[1] 

机构地区：[1]中国药科大学药物代谢动力学重点实验室,江苏南京210009

出　　处：《药学进展》2013年第5期215-221,共7页Progress in Pharmaceutical Sciences

基　　金：科技基础设施建设计划--江苏省创新平台提升项目(No.BM2012012);国家"十二五"重大新药创制资助项目(No.2012ZX09103-101-031)

摘　　要：聚腺苷二磷酸核糖聚合酶(PARP)是关键的DNA单链损伤修复酶,近年来研究发现,PARP抑制剂不仅可增加肿瘤对放化疗的敏感程度,还能被单独用于同源重组修复缺陷的肿瘤的治疗,具有良好的应用前景。对临床在研的PARP抑制剂的抗肿瘤作用研究近况进行介绍,旨在为相关药物的研发提供参考。Poly （ADP-ribose） polymerase （PARP） is a critical enzyme in DNA single-strand damage repair. Recently, more and more researches have shown that PARP inhibitors can improve the sensitivity of tumors to radiotherapy and chemotherapy, and selectively kill homologous recombination repair-defective tumors as monotherapy. They have good prospect in clinical application. The research status of PARP inhibitors in anti-tumor therapy was reviewed in this paper, so as to provide reference for the development of related new drugs.

关 键 词：聚腺苷二磷酸核糖聚合酶抑制剂 抗肿瘤活性 新靶点 临床研究 

分 类 号：R96[医药卫生—药理学]